Novavax Looks Primed and Ready for a Vaccine Comeback

The race to manufacture a Covid-19 vaccine started with Novavax (NASDAQ:NVAX) among the major contenders. However, that seems like eons ago considering the state we find NVAX stock in today. Shares of the biotech have been losing steam for several months now. Although attributable to several factors, this is mostly the company’s own doing. This year, Novavax delayed submitting its application for U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) several times. Source: Asc


Please enter your comment!
Please enter your name here